Navigation Links
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Date:11/3/2011

MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the 56-week EQUIP study were published in Obesity, the peer-reviewed journal of The Obesity Society. The EQUIP study evaluated the efficacy and safety of the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 kg/m2) patients across 91 sites in the US. In addition to average weight loss of 14.4% of initial body weight among those who completed the study at the top dose of Qnexa, severely obese patients had improvements in blood pressure, glucose, triglycerides and cholesterol. The results with Qnexa suggest the potential to effectively treat severely obese patients without surgery.

"Obesity is a serious medical condition that threatens the public health and reduces the quality and length of lives. Currently available treatments are limited and options are needed," said lead investigator Dr. David Allison, director of the Nutrition Obesity Research Center, University of Alabama at Birmingham. "In this population of severely obese patients, those taking Qnexa experienced significant weight loss and reduction in risk factors for many chronic diseases. The results refute a common notion that nonsurgical treatments are not effective for extremely obese persons. The findings are especially relevant to the 14% of the US adult population classified as extremely obese."

Patients in the study had a baseline body mass index of >/= 35 kg/m2, and an average initial weight of 256 pounds. Treatment was well tolerated, with no evidence of serious adverse events induced by treatment.

Specific weight loss results for all patients through 56 weeks as published in Obesity are as follows:

  • Least-squares (LS) mean weight loss for Qnexa patients who completed the EQUIP study was 14.4% and 6.7% with top-dose Qnexa
    '/>"/>

  • SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
    2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
    3. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
    4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
    5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
    6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
    7. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
    8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
    9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
    10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
    11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
    (Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
    (Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
    Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
    ... Feb. 28, 2012  Today, Jeanne Monahan , ... Human Dignity , testified before the House Judiciary Committee ... titled "Executive Overreach: The HHS [Department of Health and ... excerpts from her testimony: (Logo: ...
    ... Company (Nasdaq: PRGO;TASE) today announced its Chairman & CEO ... Healthcare Conference on Wednesday, February 29th, at 3:30 PM ... York City, New York. Perrigo Company ... and distributes OTC and generic prescription (Rx) pharmaceuticals, infant ...
    Cached Medicine Technology:FRC's Jeanne Monahan Testifies Before House Judiciary Committee, Urges Repeal of Discriminatory Mandate 2Perrigo Company to Present at the RBC Capital Markets' Healthcare Conference 2
    (Date:7/11/2014)... Anterior Cruciate Ligament (ACL) happens all too frequently, however ... Orthopaedic Society for Sports Medicine,s (AOSSM) Annual Meeting suggests ... may minimize the chance of a future ACL tear. ... factors such as, age, activity level and type of ... said lead author, Christopher C. Kaeding, MD of the ...
    (Date:7/11/2014)... NY (PRWEB) July 11, 2014 Wild by ... is proud to announce they are opening a fifth store ... Wild by Nature offers one of the largest selections of ... people diagnosed with celiac disease, these stores have become a ... gluten-free diet. , Gluten sensitivity, and gluten intolerance, is a ...
    (Date:7/11/2014)... BellasDress, the experienced dressmaker in the ... suppliers when it comes to beach wedding dresses ... of beach wedding outfits in its online shop. Included ... outfits. , BellasDress has been considered as one ... to the company’s senior spokesman, BellasDress provides superb special ...
    (Date:7/11/2014)... Growing old was thought of as a fate that was ... was shown that many of the “myths” people associate with ... out, the elderly can still live quite as fruitfully as their ... time in the world, older people also need to live a ... the twilight of their lives. This is why Guy Coalter, the ...
    (Date:7/11/2014)... July 11, 2014 Plasma resource reserves ... products industry. Although the closure of 16 plasma collection ... to domestic blood products market, the total plasma volume ... on year and total lot release volume declined by ... stock consumption, insufficient utilization of new plasma stations and ...
    Breaking Medicine News(10 mins):Health News:Wild by Nature Opens New Location 2Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2Health News:It’s All Free For Seniors Review, How To Take Advantage of What Life Has to Offer In Old Age – Vinamy.com 2Health News:It’s All Free For Seniors Review, How To Take Advantage of What Life Has to Offer In Old Age – Vinamy.com 3Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 3Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 4
    ... of your New Year resolutions, The Alliance for Aging Research// ... of both physical as well as mental exercise to stay ... nonprofit Alliance for Aging Research said, "There is a lot ... prevent or lessen the cognitive decline that often comes with ...
    ... habit of offering fruit juices and sugar added beverages ... better to avoid sugary drinks in cups with sippers ... the sipper attached. The American Academy of Pediatric Dentistry (AAPD) ... cups do help to avoid liquids from spilling over from ...
    ... for patients in ICU by adhering to simple techniques ... infections. // ICUs can become thoroughly aseptic by ensuring ... and catheters. A detailed report was made by experts ... the report are published in New England Journal of ...
    ... parents to encourage their children to put away the video ... AMA Vice President, Dr Choong-Siew Yong, said today. ... soccer balls and tennis racquets are a great way to ... ,“Swimming or horse-riding lessons, bicycle outings, backyard cricket, or just ...
    ... junta, left for Singapore to receive treatment for an intestinal ... who has led Myanmar's junta - the self-styled State Peace ... the country Sunday on a special flight arranged by businessman ... ,An informed source in the government said Than Shwe, ailing ...
    ... the calories a person consumes can prevent, or at least ... suggests// that body composition – whether a person is ... risks. ,In other words, how the body ... than how many or how few calories are consumed—a finding ...
    Cached Medicine News:Health News:Simple Steps to Safe Guard Patients from Bloodstream Infections in ICU 2Health News:Keep Kids Active in the Holidays 2Health News:Body Composition Is Key Player in Controlling Cancer Risks 2
    This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,411-9) or contact custom...
    ... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features: Eppendorf ...
    ... Seven digital models cover the range from 2ul ... fluently. Volume lock design prevents inadvertent volume ... horizontal grip. Whole pipette is autoclavable at ... is all polypropylene. Suitable for one-handed operation. ...
    ... a fully adjustable, air-displacement pipette with a ... latest member of the Pipetman family, sharing ... and precision. We also added a number ... customers. Eight models cover the full range ...
    Medicine Products: